Alzheon Initiates the P-III (ORION-E4) Trial of Valiltramiprosate (ALZ-801) for Alzheimer’s Disease

Shots: Alzheon has launched the P-III (ORION-E4) trial evaluating valiltramiprosate (ALZ-801; 265mg, BID) vs PBO for 78wks. in ~550 APOE4/4 homozygotes with MCI due to Alzheimer’s disease across ~150 sites in ~12 countries; 1EP: change in CDR-SB at Wk. 78 New P-III (APOLLOE4) analyses to be presented at CTAD 2026 showed 39% lower incidence of new ARIA-H lesions (15% vs 26%) & sustained plasma p-tau217 reductions, with a 53% difference vs PBO in the MCI subgroup ALZ-507, a once-daily next-gen anti-amyloid aggregation inhibitor & APOE4 corrector, is completing P-I studies Ref: Alzheon  |   Image: Alzheon  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Alzheon Initiates the P-III (ORION-E4) Trial of Valiltramiprosate (ALZ-801) for Alzheimer’s Disease appeared first on PharmaShots.